You are here: Industry Insights > Market News > Luye Pharma’s Shares Drop on Acquisition of Two Biological Antibodies

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate

Neohesperidin

Advantame

Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench

Pharma and Food Grade, USP/FCC Neotame Sweetener E961

Trilobatin

Luye Pharma’s Shares Drop on Acquisition of Two Biological Antibodies

firstwordpharmaDecember 25, 2018

Tag: clinical development , monoclonal antibody , LUYE PHARMA , clinical development

Favorites

Luye Pharma announced that it acquired the biological monoclonal antibodies, LY01011 and LY09004, from Shandong Boan Biological Technology for nearly $73 million, reported Investing.com.

Both drugs are in clinical development and are expected to launch in 2023, if approved.

Shandong Luye will pay 60 percent of the agreed amount five days after signing the agreement, and another 20 percent five days after Boan completes the Phase III trial of the compounds.

The remaining 20 percent will be due five days after China's National Medical Products Administration clears the products.

Previous:Nature publication reports first-in-human trial of a novel actively personalized therapeutic vaccine for brain cancer

Next:FDA clears Zydus Cadila to market generic versions of Mayne Pharma's Doryx, Takeda's Uloric

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Luye Pharma’s Shares Drop on Acquisition of Two Biological Antibodies | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

Luye Pharma’s Shares Drop on Acquisition of Two Biological Antibodies

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may like
More>>

Luye Pharma’s Shares Drop on Acquisition of Two Biological Antibodies

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may likeMore>>

You may like
More>>